Dernières nouvelles pour Solventum (NYSE:SOLV) Stock

Solventum

Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Solventum Corp

SOLVE

SOLVAC SA by SOLVAC SA

SOLVBL SOLUTIONS INC by SOLVBL SOLUTIONS INC.

SoLVBL Solutions Inc

SOLVAY BANK SOLVAY NY by Solvay Bank (NY)

Solvay Bank

Solvay SA

HC Wainwright &amp; Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) with a Buy and maintains $40 price target.

News

Price Target

Reiteration

Analyst Ratings

MNPR

HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $40 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Hold rating. Microsoft shares closed at $375.39 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy rating and announced a price target of $195. Oracle shares closed at $139.81 on Monday. <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Scott Buck initiated coverage on Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) with a Buy rating and announced a price target of $4. Rezolve AI shares closed at $1.21 on Monday. <a href="https://www.benzinga.com/quote/RZLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy rating and announced a price target of $280. Amazon shares closed at $190.26 on Monday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Buy rating and announced a price target of $210. Alphabet shares closed at $156.23 on Monday.  <a href="https://www.benzinga.com/quote/GOOG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01071912/image-1-2-1024x584.png" alt="" class="wp-image-850926" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01071912/image-1-2-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01071912/image-1-2-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01071912/image-1-2-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01071912/image-1-2.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Image via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

AMZN

GOOG

MSFT

ORCL

RZLV

This Amazon.com Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

On Monday, Chinese electric vehicle company XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) announced its vehicle delivery results for March and the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44575805/xpeng-announces-vehicle-delivery-results-for-march-and-first-quarter-2025" rel="noreferrer noopener">first quarter of 2025</a>.
In March, XPeng delivered 33,205 Smart EVs, implying a 268% growth, surpassing 30,000 units for the fifth consecutive month.
For the first quarter of 2025, XPeng delivered 94,008 Smart EVs, a 331% increase over last year.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44492590/alibaba-and-bmw-team-up-to-bring-ai-powered-smart-assistant-to-next-gen-cars-in-china" rel="noreferrer noopener">Alibaba, BMW Team Up To Bring AI-Powered Smart Assistant In Next-Gen China Cars</a>
On March 13, 2025, at its Spring 2025 Launch conference, XPeng launched 2025 versions of the XPeng G6 and XPeng G9.
Both upgraded versions come standard with 5C AI batteries and Turing AI-powered smart driving features across all trims.
In March 2025, XNGP&#8217;s monthly active user penetration rate in urban driving reached 86%. At the same time, XPeng expanded its global presence by entering the Indonesian market.
Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44579335/li-auto-inc-march-2025-delivery-update" rel="noreferrer noopener">announced on Tuesday it delivered</a> 36,674 vehicles in March 2025, marking a 26.5% growth. This brought its first-quarter deliveries to 92,864, up by 15.5%. As of March 31, 2025, Li Auto&#8217;s cumulative deliveries reached&nbsp;1.226 million.
As of March 31, 2025, the company had 500 retail stores in 150 cities, 502 servicing centers, and Li Auto-authorized body and paint shops in 225 cities. It also had 2,045 supercharging stations in China equipped with 11,038 charging stalls.
NIO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) announced it delivered 15,039 vehicles in March 2025, representing a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44579887/nio-inc-provides-march-and-first-quarter-2025-delivery-update" rel="noreferrer noopener">growth of 26.7%</a>. The deliveries comprised 10,219 vehicles from its premium smart electric vehicle brand NIO and 4,820 from the company&#8217;s family-oriented smart electric vehicle brand ONVO. The company delivered 42,094 vehicles in the first quarter of 2025, marking a growth of 40.1%. Cumulative deliveries reached 713,658 as of March 31, 2025.
XPeng stock surged 167% in the last 12 months. The EV company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44373548/teslas-china-rival-xpeng-delivers-over-91500-evs-in-q4-eyes-massive-growth-in-q1" rel="noreferrer noopener">fourth-quarter revenue</a> growth of 23.4% to 16.11 billion Chinese Yuan ($2.21 billion), topping the&nbsp;consensus estimate&nbsp;of&nbsp;16.02 billion Chinese Yuan. Quarterly vehicle deliveries&nbsp;rose 52.1% to 91,507, backed by its sales network of 690 stores and 1,920 charging stations.
The company expects revenue of 15 billion Chinese Yuan-15.7 billion Chinese Yuan, compared to the consensus of 14.684 billion Chinese Yuan. XPeng and long-term partner German automaker&nbsp;Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) plans to build a <a target="_blank" href="https://www.benzinga.com/25/01/42807958/xpeng-volkswagen-to-jointly-build-super-fast-ev-charging-network-in-china" rel="noreferrer noopener">super-fast charging network</a> in China.
Meanwhile, Li Auto and Nio stocks lost 18% in the last 12 months. Nio <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44452057/teslas-chinese-rival-nio-warns-of-disappointing-q1-results-deliveries-revenue-set-to-miss-estimates" rel="noreferrer noopener">continues to face</a> challenges in achieving full-year profitability, primarily due to high research and development expenses and significant operational costs.
Price Action: XPEV stock is up 3.09% at $21.36 premarket at the last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44568964/amd-powers-oracle-cloud-with-new-epyc-chips-promising-major-boost-in-performance" target="_blank" rel="noreferrer noopener">AMD Powers Oracle Cloud With New Epyc Chips Promising Major Boost In Performance</a></li>
</ul>
Photo via Shutterstock.

Equities

Movers

VWAGY

XPEV

China's XPeng Clocks Record Q1 EV Sales, Deliveries Surge 3.6X

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $15 to $8.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $8

General

IONQ

IonQ's Recently Commissioned Quantum Computer Forte Enterprise Now Available Through Amazon Braket And IonQ Quantum Cloud

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) with a Buy and raises the price target from $2 to $21.

PHGE

HC Wainwright & Co. Maintains Buy on BiomX, Raises Price Target to $21

D. Boral Capital analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $12 to $1.

CARM

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $1

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) with a Buy and maintains $16 price target.

CALC

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

Endeavour Silver Expands Into Peru With $145M Acquisition Of Minera Kolpa And Huachocolpa Uno Mine

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

LASE

Laser Photonics Bags Order For CleanTech Industrial Roughening Laser 3040 From MRO Products Distributor Grainger

Bitfarms Ltd. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BITF#TSX">BITF</a>), a global energy and compute infrastructure company, today issued its latest monthly production report. All financial references are in U.S. dollars.
CEO Ben Gagnon stated, "March was a very productive month for Bitfarms. We successfully closed both our transformative acquisition of Stronghold Digital Mining, the largest M&amp;A deal between two public miners in our industry, and the strategic sale of our 200 MW Yguazu data center. Through these transactions, we have rebalanced our portfolio to the U.S. where we expect to achieve greater yields per MW, reduced our average cost of power across our portfolio, minimized our 2025 capex requirements, and secured highly desirable sites that will enable us to diversify beyond Bitcoin mining into HPC/AI and energy generation.
"In addition, we advanced our HPC/AI strategy with both the appointments of James Bond, SVP of HPC, and Craig Hibbard, SVP of Infrastructure, and the continued evaluation of our three Pennsylvania sites for potential HPC conversion. Initial studies from our strategic partners confirmed that all three sites are well-suited: they are strategically located near other data center campuses and peering hubs and they have the necessary power, land and fiber infrastructure to support HPC. We expect to receive full, detailed feasibility studies in Q2. With the steps we've taken in Q1, we now have the properties, internal team, and strategic engineering and marketing advisors in place, taking a holistic approach to advancing our HPC/AI business."
SVP of Global Mining Operations Alex Brammer said, "During March we grew our operational hashrate 21% to 19.5 EHuM and reached our Q2 efficiency target of 19 w/TH three months ahead of schedule. Our energy portfolio is now larger and more efficient, with stronger operating economics and significant U.S. growth potential."
March 2025 Select Operating Highlights
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Key Performance Indicators</td>
<td>March 2025 (proforma)</td>
<td>February 2025</td>
</tr>
<tr>
<td>Total BTC earned</td>
<td>280</td>
<td>213</td>
</tr>
<tr>
<td>Month End Operating EHuM</td>
<td>19.5</td>
<td>16.1</td>
</tr>
<tr>
<td>BTC/Avg. EH/s</td>
<td>17</td>
<td>16</td>
</tr>
<tr>
<td>Average Operating EHuM</td>
<td>16.4</td>
<td>13.4</td>
</tr>
<tr>
<td>Energized Capacity (MW)</td>
<td>461</td>
<td>437</td>
</tr>
<tr>
<td>Watts/Terahash Efficiency (w/TH)</td>
<td>19</td>
<td>20</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<ul>
<li>19.5 EHuM operational at March 31, 2025, up 21% M/M.</li>
<li>16.4 EHuM average operational, up 22% M/M.</li>
<li>17 BTC/average EHuM, 6% higher M/M.</li>
<li>280 BTC earned on a proforma basis, 31% higher M/M.</li>
<li>9.0 BTC earned daily on average, equal to ~$738,000 per day based on a BTC price of $82,000 at March 31, 2025. &nbsp;</li>
</ul>
March 2025 Financial Update
<ul>
<li>Total liquidity of $132 million, including approximately $39 million in cash at March 31, 2025.</li>
<li>Treasury of 1,140 BTC, down from 1,260 BTC last month and representing $93.4 million based on the Bitcoin price of $82,000 at March 31, 2025.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

BITF

TSX:BITF

Bitfarms Reports 31% Increase in BTC Earned in March, Surpassing 280 BTC for the Month

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

ATNM

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

BECN

QXO Extends And Amends Tender Offer For Beacon Roofing Supply, Raising Price To $124.35 Per Share

SMTK

Smartkem Posts FY24 Revenue Of $82,000 And a Net Loss Of $(10.3)M

Earnings

Earnings Misses

AMPG

AmpliTech Gr FY Sales $9.510M Miss $17.000M Estimate, Cash Balance of $19.3M

HC Wainwright &amp; Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) with a Buy and maintains $6 price target.

SABS

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target

Management

Press Releases

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Trian Comments on Solventum's Sale of its Purification & Filtration Business

Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City

Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Mutual Funds

Alger Russell Innovation Index Updates for First Quarter 2025

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

Comments

Solventum

Actualités

Dernières nouvelles pour Solventum (NYSE:SOLV) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL